PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.\', \'Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.\', \'Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.\', \'Department of Physiology, Eastern Medical College, Cumilla, Bangladesh.\', \'Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria.\', \'Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh.\', \'Department of Surgery, Nelson R Mandela School of Clinical Medicine, University of KwaZulu-Natal, Umbel, Berea, South Africa.\', \'Department of Physical Rehabilitation Sciences, Kulliyyah of Allied Health Sciences, International Islamic University Malaysia, Kuantan, Malaysia.\', \'Unit of Community Medicine. Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur, Malaysia.\', \'Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur, Malaysia.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/14740338.2021.1946513
?:hasPublicationType
?:journal
  • Expert opinion on drug safety
is ?:pmid of
?:pmid
?:pmid
  • 34162299
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.112
?:rankingScore_hIndex
  • 60
is ?:relation_isRelatedTo_publication of
?:title
  • Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all